Approximately 25–35% of patients with malignant rhabdoid tumours (MRTs) carry a germline SMARCB1 alteration, which defines the Rhabdoid Tumour Predisposition Syndrome type 1 (RTPS1) [12–15, 146, 147]. Here, SMARCB1 is linked to rhabdoid tumor predisposition syndrome 1.